Moleculin Biotech, Inc. · NASDAQ:MBRX
Moleculin Biotech — Q3 2023 Earnings Presentation
26 slides from Moleculin Biotech's earnings presentation, Nov 13, 2023
Slide 1: Q3 2023 Financial Results and Pipeline Update
Slide 2: Disclaimer
Disclaimer Allstatements contained herein other than statements of historical fac, including statements regarding our future results of operations and financial position, ‘our business strategy and plans, and our objectives for future operations, are forward-looking statements. The words “believe,”
Slide 3: ‘ Bworecuun od g
‘ Bworecuun od g
Slide 4: Core Management Belief...
Core Management Belief... The most important first line tool for AMLand Advanced STS is an anthracycline. We are making this tool available to an otherwise inaccessible class of patients.
Slide 5: We Are Advancing Annamycin
We Are \ H (© Annamycin Advancing DT a ncaa naraiuacat aire with notable signs of efficacy in AML and STS A growing pipeline of clinical programs to treathighly resistant Pipeline Expansion cancers and viruses Opportunities for additional high-value oncology indications ® Global Expert Network & Str
Slide 6: Priority Drug Candidate Development Pipeline
Priority Drug Candidate Development Pipeline ae Orphan rugDesgnaioninAML&STS a PeoTEEecmerCSS Annamycin Potential for additional indications ot Tse aco Dae ee eereleeea ane an WP1066 Including DPIG (one adult and one pediatric) Phase 2 develo nt Biworecoum
Slide 7: Traditional Anthracycline Cardiotoxicity Creates Significant Need
Traditional Anthracycline Cardiotoxicity Creates Significant Need for Next-Generation Anthracyclines f Cardiotoxicity Limits Application, Number of Treatments, and Efficacy Limitations of Current Anthracyclines Increased Risk for Relapsed or Refractory Disease specifically in AML. 18 Limited Respons
Slide 8: Traditional Anthracycline Cardiotoxicity Accumulates Over Time and Limits Efficacy
Traditional Anthracycline Cardiotoxicity Accumulates Over Time and Limits Efficacy Estimated Cumulative Percentage of Patients Dose Related Risk of Doxorubicin-Induced Conges with On Study Cardiac Events, by Cumulative Dose Heart Failure (CHF); Patients with CHF by Cumulative PMOLECULIN
Slide 9: AML and STS Lung Metastases Opportunity for Safer Anthracycline
AMLand STS Lung Metastases Opportunity tg \ for Safer Anthracycline More than half of patients newly diagnosed with AML The prognosis for patients with advanced or cannot receive the recommended initial intensive metastatic STS is poor, with an estimated chemotherapy due to older age or poor health.
Slide 10: Limitation for Current Standards of Care (SOC)
Limitation for Current Standards of Care (SOC) First Line Therapyin AMLandSTS Indications is Doxorubicin AML: Ven+Aza CR of 30-40% STS: “50% PFS 3 Months 2°4/34 Line Elderlyand Unfit 24 and 3"4Line Complete Response Rate of Progression Free Survival Venclexta (SOC) in AML with SOCin STS VENCLEXTA FD
Slide 11: Annamycin: The Next Generation Anthracycline
Annamycin: The Next Generation Anthracycline Chemotherapy ont Annamycin Annamycinis a next-generation, non-cardiotoxic anthracycline demonstrating both safety and promising early activity across multiple clinical studies for AML and STS lung metastases Clinical Highlights * AML * STS * Phase 1B comp
Slide 12: Advantages of Annamycin Over Traditional Anthracyclines
Advantages of Annamycin Over Traditional Anthracyclines —— Validation Methods LVEF Evaluation ECHO Strain Evaluation, by CentralLab Hair lose incidence < 65% 92%with Non-Cardiotoxic Highy Sersitive Cardiac cheesy B Biomarkers of Troponin Potentialto multi-drug, Assessments from Independent resistanc
Slide 13: The Full Annamycin Opportunity
The Full Annamycin Opportunity Potential for Significant Upside —— 60k Pancreatic Liver — 13,500 ek ‘STS Lung Metastases gee Endometrial Lung, 104K — 20,000 Initial Annamycin ‘Acant Myelcid Colorectal Target Indications Leukerria caarees Liver TOTAL INCIDENCE \ ~33.5K TOTAL INCIDENCE ei ~A78K Lung.
Slide 14: Global Network
Global Network All technology licensed from MD Anderson Cancer Center (MDACC) ‘Supports continuing preclinical research on our technology at MDACC close to $1M per year ‘Supports preclinical research at UTMB Past & current externally funded trials— MD Anderson Cancer Center; Emory University, Aflac
Slide 15: Preclinical Data Driving Annamycin Clinical Direction
Preclinical Data Driving Annamycin Clinical Direction AMLt Sis? Preclinical Study at MD Anderson Demonstrated 68% Improvement in Overall Survival with ‘Annamycin+ARA-C vs. Annamycin Alone. Greater Accumulation in Lungs for Increased Therapeutic Benefit Survival Benefits of AnnamycinandARA.C Concentr
Slide 16: Dr. John Paul Waymack
Dr. John Paul Waymack Senior Chief Medical Officer
Slide 17: Advancing Annamycin in AML
Advancing Annamycin in AML Phase 1: MB-104 MONOTHERAPY 6 17% CR Tiiallocition-US Dosing lrted by FDA Lifetime Anthrayctine| ose (LIMAD) + Wolttolerated inthe study population + Limited te low doses + Morphologicleukoria free state was achiovedin cone subject inthe 120 me/n? cohort + Domonstratd sao
Slide 18: Significant Patient Experiences in MB-106 Annamycin + Ara-C
Significant Patient Experiences in MB-106 Annamycin + Ara-C | ‘Age (Yis) Relapsed 78-Relapsed or Refractory v pemeav(aa 2 Arm Study (7 mos) Ven/Aza (17 mos) Best Response in srablecR MB-106 Durable Ct ‘Annamycin Dose (Course) 190 me/ine ts (3 courses) Durability 8 mos (and climbing) UTMAD 1140 mg/m?
Slide 19: Annamycin Demonstrates Efficacy in STS Lung Metastases (MB-107)
Annamycin Demonstrates Efficacy in STS Lung Metastases (MB-107) Demonstrated Stable Disease After Demonstrated Improvement with Dose < 330 mg/m? ‘Two Treatment Cycles and Fewer Prior Therapies ‘MB-107 Summary to Date All Subjects in Phase 18 100% 100% 100% 100K 100% Ce, Free See ee eee ihm SS aE 22
Slide 20: Jonathan P. Foster
Jonathan P. Foster Executive VP & Chief Financial Officer <SiMOLECULIN
Slide 21: Cash to Fund Operations into the Third Quarter of 2024
Cash to Fund Operations into the Third Quarter of 20241 Nasdaq: MBRX ~$24.6M Cash Balance? ~$16.3M Market Cap? ~29.8M Shares Outstanding* ~156K3 Month Avg. Volume?
Slide 22: Upcoming Milestones
Upcoming Milestones In-depth data review and presentation of, topline data on MB-106 clinical trial Q4 2023 into 1H 2024 : MB-106 End of Phase 2 (EOP2) Meeting 1H 2024 Annamycin [For2| Meeting AML Identify next Phase of Development / Pivotal Program 1H 2024 Initiate pivotal program 2H 2024 into 14 2
Slide 23: Moleculin
= eftMOLECULIN 5
Slide 24: Annamycin Demonstrated Non Cardiotoxic, Now with Efficacy
Outof 66 participants across multiple studies, with 62 confirmed by independent review Annamycin Demonstrated 100% & Non Cardiotoxic Now with Efficacy
Slide 25: Core Management Belief...
Core Management Belief... The most important first line tool for AMLand Advanced STSis an anthracycline. We are making this tool available to an otherwise inaccessible class of patients.
Slide 26: Moleculin
y S ay =~) MOLECULIN 92 NASDAQ: MBRX | mole